echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Clin Cancer Res: Scientists have identified new potential targets for immunotherapy for melanoma.

    Clin Cancer Res: Scientists have identified new potential targets for immunotherapy for melanoma.

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A recent study published in the International Journal of the Institute of Medicine and other scientists through a study revealed why some melanoma patients do not respond to immunotherapy related findings or can help researchers develop new targeted therapies to treat potentially fatal cancersImage caption The Australian Institute of Health and Welfare, which has the highest incidence of melanoma in the world, estimates that more than 10,000 people were diagnosed with melanoma in Australia last year and died in many deathsIn the study, researchers who found that a particular protein called a protein in human melanoma cells may make skin cancer more difficult to treat with immunotherapy Researchers have revealed the importance of the effectiveness of immunotherapy in patients with metastatic melanoma, which has not been previously found in the human bodyTumors appear to use molecules to evade the hunt of immune cells and also to resist the killing of immunotherapy; proteins can be expressed in almost all cancer cells but are expressed less often in normal cells, including certain immune cells, which are part of a family of adhesion sadgens that are important for cell-to-cell interactionsThe researchers say current immunotherapy can help untie the immune system to kill melanoma cells, but in some patients tumor cells still hide in the body, making the treatment ineffective and eventually lead to the patient's deathHigh levels in melanoma cells seem to help tumors evade cell detection and can trick cells from touching tumors during interaction stumors that appear to damage the cell's ability to recognize and kill tumor cells and reduce tumor levels in metastatic melanoma patients' bodies as a new way to improve the efficiency of immunotherapy and save more patients' livesIn the article, the researchers used new imaging techniques to analyze pre-treatment tumor samples collected from the patient's body and then linked tumor levels to the patient's prognosisThe researchers said the imaging results showed that patients with high levels of melanoma who carried high levels were often in poor health and did not respond to immunotherapy; There is currently no therapeutic approach to melanoma that can target the effects, so the researchers hope to further study the development of new immunotherapy to target the action protein to inhibit tumor developmentThe study, based on a study by researchers in the year, shows that tumors and immune cells are critical to tumor growth and spread later researchers hope to analyze in-depth research whether other cancers play a key role in the response to immunotherapy() Original origin:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.